Association of glucagon-like peptide-1 receptor agonist use with anxiety disorders, depression, self-harm, and suicidality: a large cohort study
Authors' conclusion
GLP-1 RAs were associated with a higher risk of anxiety disorders and depression, but no difference in suicidality or self-harm in comparison to SGLT2i, DPP4i, and lower suicidality risk compared to SU.
Study context
- Population
- Adults (≥18 years) with T2D on metformin who initiated GLP-1 RAs, SGLT2i, DPP4i or SU between 1 April 2013 and 31 December 2019; TriNetX3 matched cohorts
- Exposure
- GLP-1 RA vs DPP-4i, SU or SGLT2i, added to metformin
- Outcome
- Incidence of anxiety disorders, depression, self-harm and suicidality
- Follow-up
- Median 5.5 years
Methodological detailspropensity-matched, electronic health records (TriNetX)
- Propensity-matched
- Electronic health records (TriNetX)
Main finding
As reported in the abstract
Depression
Hazard ratio (95% CI)
GLP-1 RAvs SGLT2i
1.19(1.11–1.28)
GLP-1 RAvs DPP4i
1.06(1.00–1.13)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Anxiety disorders · median follow-up 5.5 yearsGLP-1 RAvs SGLT2i | 1.09 (1.02–1.16) | |
| Anxiety disorders · median follow-up 5.5 yearsGLP-1 RAvs DPP4i | 1.07 (1.02–1.13) | |
| Suicidal ideation · median follow-up 5.5 yearsGLP-1 RAvs SU | 0.62 (0.44–0.87) | |
| 0.512Hazard ratio (log scale) |
Original publication
Association of glucagon-like peptide-1 receptor agonist use with anxiety disorders, depression, self-harm, and suicidality: a large cohort study. Diabetes Res Clin Pract. Published 25 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →